Abstract

Personalized medicine is based on rapid development of genetics and availability of tumour molecular profiling. Information from the large scale of genes of panel testing provides a possibility for targeted therapy, which prolongs cancer patients’ survival. Tumour molecular profiling is becoming an important part of the cancer treatment plan. Characterization of cancer somatic mutations as a diagnostic tool for targeted therapy has occupied a place in the patient’s first line treatment plan. More widespread usage of cancer gene panel testing can be expected in the nearest future. The results of panel tests should be discussed on molecular tumour boards.